ofloxacin has been researched along with diclofenac in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.86) | 18.7374 |
| 1990's | 1 (2.86) | 18.2507 |
| 2000's | 16 (45.71) | 29.6817 |
| 2010's | 14 (40.00) | 24.3611 |
| 2020's | 3 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Avdeef, A; Tam, KY | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Campillo, NE; Cañada, FJ; Canales, A; Carvalho, I; Chierrito, TPC; Martinez, A; Martínez-Gonzalez, L; Pedersoli-Mantoani, S; Perez, C; Pérez, DI; Roca, C; Sebastian-Pérez, V | 1 |
| Bishai, WR; Duan, G; Gunosewoyo, H; Liu, LL; Lun, S; Tang, J; Xiao, S; Yang, F; Yu, LF; Zhang, W | 1 |
| Asif, M; Husain, A; Iqbal, MA; Iram, F; Khan, SA | 1 |
| Balliano, TL; Barbosa, G; Carvalho, VF; da Silva, BA; de Souza, ET; Lima, LM; Martins, IRR; Martins, MA; Medeiros, MM; Moraes Junior, MO; Nunes, IKDC; Silva, PMR; Silva, SWD | 1 |
| Rehavi, M; Rubinstein, E; Segev, S | 1 |
| Akaki, T; Kawahara, S; Sato, K; Shimizu, T; Tomioka, H | 1 |
| Ong-Tone, L | 1 |
| Ferrari, B; Fraysse, B; Garric, J; Lo Giudice, R; Mons, R; Paxéus, N; Pollio, A; Vollat, B | 1 |
| Drillia, P; Fountoulakis, M; Lyberatos, G; Stamatelatou, K | 1 |
| Dokianakis, SN; Kornaros, ME; Lyberatos, G | 1 |
| Ambrosi, A; Antiochia, R; Campanella, L; Dragone, R; Lavagnini, I | 1 |
| Drillia, P; Lyberatos, G; Stamatelatou, K | 1 |
| Cañada-Cañada, F; Espinosa-Mansilla, A; González Gómez, D; Muñoz de la Peña, A | 1 |
| Aberer, W; Arbab, E; Grims, R; Komericki, P; Kränke, B | 1 |
| Hu, J; Liu, H; Liu, X; Wang, G; Xie, L | 1 |
| Fountoulakis, MS; Lyberatos, G; Stamatelatou, K | 1 |
| Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Di Colo, G; Pedreschi, E; Zambito, Y | 1 |
| Khan, MA; Manzoor, S; Salam, FA; Shoaib, MH; Sultan, F; Yousuf, RI | 1 |
| Bleumink, R; Bol-Schoenmakers, M; Fiechter, D; Kruijssen, L; Kwast, L; Ludwig, I; Pieters, R; Smit, J | 1 |
| Cruz-Monzon, J; De La Cruz-Noriega, M; Gallozzo Cardenas, M; Gamez-Jara, A; Rodríguez-Serin, H; Rodriguez-Yupanqui, M; Rojas-Flores, S | 1 |
| Ping, Q; Yang, H; Zhang, Y | 1 |
3 review(s) available for ofloxacin and diclofenac
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Insights into the chemistry and therapeutic potential of furanones: A versatile pharmacophore.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Antineoplastic Agents; Antiviral Agents; Humans; Molecular Structure | 2019 |
Literature Review: Evaluation of Drug Removal Techniques in Municipal and Hospital Wastewater.
Topics: Anti-Bacterial Agents; Carbamazepine; Diclofenac; Hospitals; Naproxen; Norfloxacin; Ofloxacin; Ozone; Pharmaceutical Preparations; Sewage; Sulfamethoxazole; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2022 |
32 other study(ies) available for ofloxacin and diclofenac
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Indoles; Molecular Structure; Piperidines; Structure-Activity Relationship | 2018 |
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Coumarins; Crystallography, X-Ray; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Polyketide Synthases; Structure-Activity Relationship; Vero Cells | 2019 |
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Enzyme Inhibitors; Humans; Hydrazones; Hypersensitivity; Lung; Male; Mice | 2020 |
Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.
Topics: Animals; Ciprofloxacin; Diclofenac; Drug Synergism; GABA Antagonists; In Vitro Techniques; Male; Muscimol; Nalidixic Acid; Ofloxacin; Quinolones; Rats; Rats, Inbred Strains; Receptors, GABA-A; Theophylline | 1988 |
[In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antitubercular; Clarithromycin; Diclofenac; Drug Therapy, Combination; Female; Levofloxacin; Mice; Mice, Inbred BALB C; Mycobacterium avium; Ofloxacin; Rifamycins; Tuberculosis | 1997 |
Use of a wick to deliver preoperative mydriatics for cataract surgery.
Topics: Anti-Infective Agents; Cataract Extraction; Cyclopentolate; Diclofenac; Drug Delivery Systems; Drug Therapy, Combination; Humans; Mydriatics; Ofloxacin; Phenylephrine; Preoperative Care; Prospective Studies; Pupil; Surgical Sponges | 2003 |
Environmental risk assessment of six human pharmaceuticals: are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment?
Topics: Animals; Carbamazepine; Clofibric Acid; Diclofenac; Drug-Related Side Effects and Adverse Reactions; Environmental Monitoring; France; Germany; Humans; Ofloxacin; Pharmaceutical Preparations; Propranolol; Risk Assessment; Sulfamethoxazole; Toxicity Tests; Water Pollutants, Chemical | 2004 |
Toxic effect of pharmaceuticals on methanogenesis.
Topics: Bacteria, Anaerobic; Biomass; Carbamazepine; Clofibric Acid; Diclofenac; Drug-Related Side Effects and Adverse Reactions; Methane; Methanomicrobiales; Ofloxacin; Pharmaceutical Preparations; Propranolol; Sewage; Sulfamethoxazole; Time Factors; Toxicity Tests; Waste Disposal, Fluid | 2004 |
On the effect of pharmaceuticals on bacterial nitrite oxidation.
Topics: Bacteria, Anaerobic; Biodegradation, Environmental; Bioreactors; Carbamazepine; Cities; Clofibrate; Diclofenac; Drug-Related Side Effects and Adverse Reactions; Kinetics; Nitrites; Nitrogen; Ofloxacin; Oxidation-Reduction; Pharmaceutical Preparations; Propranolol; Sewage; Sulfamethoxazole; Triclosan; Waste Disposal, Fluid; Water Purification | 2004 |
Electrochemical determination of pharmaceuticals in spiked water samples.
Topics: Clofibric Acid; Diclofenac; Electrochemistry; Environmental Monitoring; Fresh Water; Ofloxacin; Pharmaceutical Preparations; Propranolol; Reproducibility of Results; Sensitivity and Specificity; Water Pollutants, Chemical; Water Pollution, Chemical | 2005 |
Fate and mobility of pharmaceuticals in solid matrices.
Topics: Adsorption; Aluminum Silicates; Bacteria, Aerobic; Bacteria, Anaerobic; Carbamazepine; Carbon; Clay; Clofibric Acid; Diclofenac; Models, Theoretical; Ofloxacin; Pharmaceutical Preparations; Propranolol; Sewage; Soil; Sulfamethoxazole; Water Movements; Water Pollutants, Chemical | 2005 |
Determinations of fluoroquinolones and nonsteroidal anti-inflammatory drugs in urine by extractive spectrophotometry and photoinduced spectrofluorimetry using multivariate calibration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemistry Techniques, Analytical; Ciprofloxacin; Diclofenac; Fluoroquinolones; Humans; Least-Squares Analysis; Mefenamic Acid; Ofloxacin; Photochemistry; Sensitivity and Specificity; Spectrometry, Fluorescence; Spectrophotometry; Spectrophotometry, Ultraviolet | 2005 |
Tryptase as severity marker in drug provocation tests.
Topics: Acetaminophen; Adolescent; Adult; Aspirin; Diclofenac; Drug Hypersensitivity; Female; Humans; Lidocaine; Male; Mefenamic Acid; Middle Aged; Ofloxacin; Penicillins; Prospective Studies; Serine Endopeptidases; Tryptases | 2006 |
Possible multiple transporters were involved in hepatobiliary excretion of antofloxacin in rats.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bile; Biological Transport; Cimetidine; Cyclosporine; Diclofenac; Enzyme Inhibitors; Erythromycin; Liver; Male; Membrane Transport Proteins; Ofloxacin; Probenecid; Rats; Rats, Sprague-Dawley; Uricosuric Agents | 2007 |
The effect of pharmaceuticals on the kinetics of methanogenesis and acetogenesis.
Topics: Acetates; Diclofenac; Kinetics; Methane; Ofloxacin; Propranolol | 2008 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
Is dialysis a reliable method for studying drug release from nanoparticulate systems?-A case study.
Topics: Chemistry, Pharmaceutical; Chitosan; Cross-Linking Reagents; Delayed-Action Preparations; Dialysis; Diclofenac; Drug Carriers; Kinetics; Nanoparticles; Ofloxacin; Polyphosphates; Reproducibility of Results; Technology, Pharmaceutical; Ultracentrifugation | 2012 |
Simultaneous quantitation of Ofloxacin, Fexofenadine HCl and Diclofenac Potassium in affixed dose combinative formulation by HPLC-UV method.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Diclofenac; Drug Combinations; Histamine H1 Antagonists, Non-Sedating; Ofloxacin; Reproducibility of Results; Spectrophotometry, Ultraviolet; Terfenadine | 2015 |
Oral exposure to immunostimulating drugs results in early changes in innate immune parameters in the spleen.
Topics: Acetaminophen; Adaptive Immunity; Administration, Oral; Animals; Carbamazepine; Cells, Cultured; Diclofenac; Drug Hypersensitivity; Female; Humans; Immunity, Innate; Immunologic Factors; Immunologic Memory; Killer Cells, Natural; Liver; Mice; Mice, Inbred C3H; Ofloxacin; Spleen; T-Lymphocytes | 2016 |
Highly efficient degradation of ofloxacin and diclofenac by composite photocatalyst aloe-emodin/PMMA.
Topics: Aloe; Catalysis; Diclofenac; Emodin; Light; Ofloxacin; Photosensitizing Agents; Polymethyl Methacrylate | 2023 |